DK3516060T3 - Antisense-oligonukleotider til behandling af øjensygdom - Google Patents
Antisense-oligonukleotider til behandling af øjensygdom Download PDFInfo
- Publication number
- DK3516060T3 DK3516060T3 DK17781030.6T DK17781030T DK3516060T3 DK 3516060 T3 DK3516060 T3 DK 3516060T3 DK 17781030 T DK17781030 T DK 17781030T DK 3516060 T3 DK3516060 T3 DK 3516060T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- antisense oligonucleotides
- eye disease
- eye
- disease
- Prior art date
Links
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title 1
- 239000000074 antisense oligonucleotide Substances 0.000 title 1
- 238000012230 antisense oligonucleotides Methods 0.000 title 1
- 208000030533 eye disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1616202.6A GB201616202D0 (en) | 2016-09-23 | 2016-09-23 | Antisense oligonucleotides for the treatment of eye deisease |
| PCT/EP2017/074133 WO2018055134A1 (en) | 2016-09-23 | 2017-09-22 | Antisense oligonucleotides for the treatment of eye disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3516060T3 true DK3516060T3 (da) | 2021-09-27 |
Family
ID=57539952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17781030.6T DK3516060T3 (da) | 2016-09-23 | 2017-09-22 | Antisense-oligonukleotider til behandling af øjensygdom |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10612025B2 (da) |
| EP (2) | EP3516060B1 (da) |
| JP (1) | JP7141123B2 (da) |
| KR (1) | KR102450757B1 (da) |
| CN (1) | CN109804069A (da) |
| AU (1) | AU2017330062B2 (da) |
| BR (1) | BR112019005586A2 (da) |
| CA (1) | CA3035627A1 (da) |
| DK (1) | DK3516060T3 (da) |
| EA (1) | EA201990644A1 (da) |
| ES (1) | ES2886118T3 (da) |
| GB (1) | GB201616202D0 (da) |
| IL (1) | IL265206B2 (da) |
| MX (1) | MX2019003361A (da) |
| NZ (1) | NZ752572A (da) |
| PL (1) | PL3516060T3 (da) |
| PT (1) | PT3516060T (da) |
| WO (1) | WO2018055134A1 (da) |
| ZA (1) | ZA201901247B (da) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201616202D0 (en) | 2016-09-23 | 2016-11-09 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of eye deisease |
| AU2020215232A1 (en) | 2019-01-28 | 2021-08-26 | Proqr Therapeutics Ii B.V. | RNA-editing oligonucleotides for the treatment of usher syndrome |
| WO2020157014A1 (en) * | 2019-01-28 | 2020-08-06 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of leber's congenital amaurosis |
| US20220177894A1 (en) | 2019-04-02 | 2022-06-09 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for immunotherapy |
| BR112021020608A8 (pt) | 2019-04-15 | 2023-03-21 | Univ Beijing | Rna recrutador de desaminase, construção, método para editar um rna alvo em uma célula hospedeira, e, construção, composição, célula, biblioteca ou kit |
| AU2020259856A1 (en) | 2019-04-18 | 2021-11-18 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of usher syndrome |
| US20220202959A1 (en) * | 2019-04-19 | 2022-06-30 | University Of Massachusetts | Gene therapies for usher syndrome (ush2a) |
| WO2020254249A1 (en) | 2019-06-21 | 2020-12-24 | Proqr Therapeutics Ii B.V. | Delivery of nucleic acids for the treatment of auditory disorders |
| PE20220300A1 (es) | 2019-07-12 | 2022-03-09 | Univ Beijing | Edicion de acido ribonucleico (arn) dirigido aprovechando la adenosina desaminasa que actua sobre acido ribonucleico endogeno (adar) utilizando acidos ribonucleicos (arn) modificados geneticamente |
| AU2020321466A1 (en) | 2019-07-26 | 2022-02-17 | Proqr Therapeutics Ii B.V. | Ophthalmic compositions comprising viscosifying polymers and nucleic acids |
| CA3159944A1 (en) | 2019-12-02 | 2021-06-10 | David HUSS | Therapeutic editing |
| CA3158528A1 (en) | 2019-12-23 | 2021-07-01 | Jim SWILDENS | Antisense oligonucleotides for nucleotide deamination in the treatment of stargardt disease |
| KR20220118512A (ko) * | 2019-12-30 | 2022-08-25 | 에디진 테라퓨틱스 (베이징) 인크. | 어셔 증후군의 치료 방법 및 그것의 조성물 |
| WO2021175904A1 (en) | 2020-03-04 | 2021-09-10 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for use in the treatment of usher syndrome |
| US20240141340A1 (en) | 2021-03-05 | 2024-05-02 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for use in the treatment of corneal dystrophies |
| WO2023134560A1 (zh) * | 2022-01-11 | 2023-07-20 | 广州瑞风生物科技有限公司 | 一种核苷酸及其应用 |
| WO2023152371A1 (en) | 2022-02-14 | 2023-08-17 | Proqr Therapeutics Ii B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
| WO2023183825A2 (en) * | 2022-03-21 | 2023-09-28 | Ptc Therapeutics Gt, Inc. | Gene therapy of ush2a-associated diseases |
| WO2024078345A1 (zh) * | 2022-10-11 | 2024-04-18 | 广州瑞风生物科技有限公司 | snRNA核酸分子及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5952221A (en) | 1996-03-06 | 1999-09-14 | Avigen, Inc. | Adeno-associated virus vectors comprising a first and second nucleic acid sequence |
| EP1191097A1 (en) | 2000-09-21 | 2002-03-27 | Leids Universitair Medisch Centrum | Induction of exon skipping in eukaryotic cells |
| US7250496B2 (en) * | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| PT2425814E (pt) | 2010-09-03 | 2013-09-02 | Novagali Pharma Sa | Emulsão de tipo água em óleo para tratamento de uma doença ocular |
| US9353371B2 (en) * | 2011-05-02 | 2016-05-31 | Ionis Pharmaceuticals, Inc. | Antisense compounds targeting genes associated with usher syndrome |
| AU2012305053B2 (en) * | 2011-09-05 | 2017-12-21 | Stichting Radboud Universitair Medisch Centrum | Antisense oligonucleotides for the treatment of Leber congenital amaurosis |
| CN103710340B (zh) * | 2013-10-12 | 2016-01-27 | 中国人民解放军总医院 | 一种i型usher综合征相关基因突变及应用此突变基因的耳聋分子病因学诊断试剂 |
| KR20160089527A (ko) * | 2013-12-12 | 2016-07-27 | 더 브로드 인스티튜트, 인코퍼레이티드 | 게놈 편집을 위한 ｃｒｉｓｐｒ-ｃａｓ 시스템 및 조성물의 전달, 용도 및 치료적 응용 |
| EP3957735A1 (en) * | 2014-03-05 | 2022-02-23 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa |
| US10131910B2 (en) * | 2014-07-10 | 2018-11-20 | Stichting Katholieke Universiteit | Antisense oligonucleotides for the treatment of Usher syndrome type 2 |
| GB201616202D0 (en) | 2016-09-23 | 2016-11-09 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of eye deisease |
-
2016
- 2016-09-23 GB GBGB1616202.6A patent/GB201616202D0/en not_active Ceased
-
2017
- 2017-09-22 CN CN201780058811.9A patent/CN109804069A/zh active Pending
- 2017-09-22 CA CA3035627A patent/CA3035627A1/en active Pending
- 2017-09-22 MX MX2019003361A patent/MX2019003361A/es unknown
- 2017-09-22 EP EP17781030.6A patent/EP3516060B1/en active Active
- 2017-09-22 ES ES17781030T patent/ES2886118T3/es active Active
- 2017-09-22 KR KR1020197010113A patent/KR102450757B1/ko active IP Right Grant
- 2017-09-22 EA EA201990644A patent/EA201990644A1/ru unknown
- 2017-09-22 NZ NZ752572A patent/NZ752572A/en unknown
- 2017-09-22 US US16/336,069 patent/US10612025B2/en active Active
- 2017-09-22 AU AU2017330062A patent/AU2017330062B2/en active Active
- 2017-09-22 BR BR112019005586A patent/BR112019005586A2/pt unknown
- 2017-09-22 EP EP21185745.3A patent/EP3985117A1/en not_active Withdrawn
- 2017-09-22 PT PT177810306T patent/PT3516060T/pt unknown
- 2017-09-22 PL PL17781030T patent/PL3516060T3/pl unknown
- 2017-09-22 DK DK17781030.6T patent/DK3516060T3/da active
- 2017-09-22 JP JP2019515876A patent/JP7141123B2/ja active Active
- 2017-09-22 WO PCT/EP2017/074133 patent/WO2018055134A1/en unknown
-
2019
- 2019-02-26 ZA ZA2019/01247A patent/ZA201901247B/en unknown
- 2019-03-06 IL IL265206A patent/IL265206B2/en unknown
-
2020
- 2020-02-07 US US16/784,410 patent/US11479771B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3516060A1 (en) | 2019-07-31 |
| PT3516060T (pt) | 2021-08-27 |
| MX2019003361A (es) | 2019-07-18 |
| US20190256847A1 (en) | 2019-08-22 |
| CN109804069A (zh) | 2019-05-24 |
| EA201990644A1 (ru) | 2019-08-30 |
| IL265206B2 (en) | 2023-08-01 |
| IL265206A (en) | 2019-05-30 |
| CA3035627A1 (en) | 2018-03-29 |
| ES2886118T3 (es) | 2021-12-16 |
| ZA201901247B (en) | 2020-10-28 |
| WO2018055134A1 (en) | 2018-03-29 |
| EP3985117A1 (en) | 2022-04-20 |
| BR112019005586A2 (pt) | 2019-06-11 |
| KR20190051020A (ko) | 2019-05-14 |
| US11479771B2 (en) | 2022-10-25 |
| JP7141123B2 (ja) | 2022-09-22 |
| NZ752572A (en) | 2023-01-27 |
| US10612025B2 (en) | 2020-04-07 |
| EP3516060B1 (en) | 2021-07-21 |
| AU2017330062A1 (en) | 2019-05-02 |
| IL265206B1 (en) | 2023-04-01 |
| JP2019528747A (ja) | 2019-10-17 |
| US20200181616A1 (en) | 2020-06-11 |
| GB201616202D0 (en) | 2016-11-09 |
| KR102450757B1 (ko) | 2022-10-04 |
| PL3516060T3 (pl) | 2021-12-13 |
| AU2017330062B2 (en) | 2024-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3516060T3 (da) | Antisense-oligonukleotider til behandling af øjensygdom | |
| DK3448999T3 (da) | Oligonukleotider til behandling af øjensygdom | |
| DK3570844T3 (da) | Azolopyrimidin til behandlingen af kræftrelaterede lidelser | |
| DK3386511T3 (da) | Fremgangsmåder til behandling af huntingtons sygdom | |
| DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
| DK3349758T3 (da) | Fremgangsmåder til behandling af arenaviridae-virusinfektioner | |
| DK3347030T3 (da) | Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme | |
| DK3261640T3 (da) | 5ht-agonister til behandling af epilepsilidelser | |
| DK3364997T3 (da) | Aspartoacylase genterapi til behandling af canavans sygdom | |
| DK3399962T3 (da) | Oftalmisk sammensætning til behandling af tør øjensygdom | |
| DK3450553T3 (da) | Mrna-terapi til behandling af øjensygdomme | |
| BR112017018413A2 (pt) | tratamento de pancreatite | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3609529T3 (da) | Rna til behandling af autoimmune sygdomme | |
| DK3390390T3 (da) | Bipyrazolylderivater egnede til behandling af autoimmunsygdomme | |
| DK3148529T3 (da) | Forbindelser til behandling af hjernecancer | |
| DK3393579T3 (da) | Øjenbehandlingssystem | |
| DK3307267T3 (da) | Behandling af multipel sklerose | |
| DK3393468T3 (da) | Fremgangsmåder til behandling af en immundefektsygdom | |
| DK3439661T3 (da) | Fremgangsmåder til behandling af øjenlidelser | |
| DK3302519T3 (da) | Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom | |
| DK3548061T3 (da) | Behandling af neurologiske sygdomme | |
| DK3210973T3 (da) | Heteroarylforbindelser til behandling af oftalmiske sygdomme | |
| DK3192524T3 (da) | Hgf præparat egnet til behandling af neurologiske lidelser |